Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Spotlight Article

What is ‘quality’ in viral vector manufacture? Strengths and limitations of current analytical tools

Viral vector bioprocessing & analytics: today’s key tools and innovation requirements to meet future demand

MARKUS HÖRER co-founded Freeline in March 2015 and serves as Chief Technology Officer and GmbH Managing Director since May 2015. Markus has 30 years’ experience working in AAV biology, as well as over 23 years’ experience in industrial vaccine and biologics development. Markus brings experience in research, process and analytical development, quality control, preclinical and business development. He joined Freeline from Rentschler, where he was responsible for setting up a Virus-based Biologics business unit, focusing on AAV vector development. Before that, from July 1996 to March 2010, he held various positions at MediGene, where he was responsible for developing AAV vector technology, its successful transfer into a GMP environment, and its use for clinical development of autologous Melanoma cell vaccines. Markus was also in charge of setting up a quality control and assay development division for an oncolytic HSV technology platform. Finally, Markus developed and was head of a novel AAVLP B-vaccine platform that was acquired by 2A Pharma, Sweden. Markus received a Ph.D. in the Department of Tumor Virology at the German Centre for Cancer Research in Heidelberg, Germany and has filed more than ten patents and claims 12 further inventions in the AAV field.

DOI: 10.18609/cgti.2020.044
Citation: Cell & Gene Therapy Insights 2020; 6(3),347-358
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog